NCT04046133View on ClinicalTrials.gov

Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 19, 2020

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Anal Cancer Stage III AAnal Cancer Stage III B
Interventions
DRUG

Pembrolizumab

Pembrolizumab, an immune checkpoint inhibitor, concomitantly with standard CRT in patients with locally advanced T3/4 anal cancer.

Trial Locations (11)

NO-0424

Oslo University Hospital, Oslo

AB25 2ZN

Aberdeen Royal Informary, Aberdeen

Unknown

Cambridge University Hospitals NHS Foundation Trust, Cambridge

Velindre Cancer Centre, Cardiff

East Suffolk and North Essex NHS Foundation Trust, Colchester

The Leeds Teaching Hospitals NHS Trust, Leeds

The Christie NHS Foundation Trust, Manchester

Oxford University Hospitals NHS Foundation Trust, Oxford

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

Swansea Bay University Local Health Board, Swansea

HA6 2RN

Mount Vernon Cancer Centre, Northwood

All Listed Sponsors
lead

Cardiff University

OTHER

NCT04046133 - Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus | Biotech Hunter | Biotech Hunter